Readministration of nivolumab for patients with advanced gastric cancer: a case series

Background: Nivolumab (NIVO), an immune checkpoint inhibitor (ICI) combined with chemotherapy, represents the standard of care for patients with human epidermal growth factor receptor 2-negative advanced gastric cancer (AGC). Although ICI readministration either as a rechallenge following disease pr...

全面介紹

書目詳細資料

發表在:	ESMO Gastrointestinal Oncology
Main Authors:	H. Kodama, Y. Narita, K. Honda, T. Masuishi, H. Taniguchi, S. Kadowaki, M. Ando, M. Tajika, T. Yamaguchi, H. Nishikawa, K. Muro
格式:	Article
語言:	英语
出版:	Elsevier 2026-03-01
主題:	gastric cancer nivolumab readministration rechallenge reintroduction
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2949819826000075